NovaBridge to Host Call for Phase 2a Wet AMD Data Review of VIS-101

summarizeSummary

NovaBridge Biosciences announced it will host a virtual business update call on March 9, 2026, to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).

check_boxKey Events

• Phase 2a Data Review Call Scheduled

  NovaBridge Biosciences will host a virtual business update call on Monday, March 9, 2026, to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).

• Key Drug Candidate VIS-101

  VIS-101 is a bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed for more potent and durable treatment benefits in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO).

• Majority Ownership in Visara

  NovaBridge is the majority shareholder of Visara, Inc., which holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories.

• Anticipated Best-in-Class Potential

  The company highlights VIS-101's potential to be a best-in-class treatment, offering more effective and durable results than current standard of care for wet AMD patients.

auto_awesomeAnalysis

NovaBridge Biosciences has scheduled a business update call to review Phase 2a clinical data for VIS-101, a key drug candidate for wet age-related macular degeneration (wet AMD). This announcement signals an imminent and significant data disclosure for a pipeline asset that the company believes has 'best-in-class' potential. Investors should monitor the March 9th call for the actual data presentation, as Phase 2a results are crucial for determining the drug's efficacy and safety and its path forward in clinical development.